Preoperative hypofractionated radiotherapy for soft tissue sarcoma

Affiliations

Comment

Falk Roeder. Lancet Oncol. 2022 Dec.

. 2022 Dec;23(12):1481-1482.

doi: 10.1016/S1470-2045(22)00686-6.

¹ Department of Radiation Oncology, Paracelsus Medical University Hospital, Salzburg 5020, Austria. Electronic address: falk.roeder@t-online.de.

No abstract available

Conflict of interest statement

I declare lecture honoraria and travel grants from IntraOp Medical and PharmaMar and participation in the advisory board of PharmaMar.

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.
Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ. Guadagnolo BA, et al. Lancet Oncol. 2022 Dec;23(12):1547-1557. doi: 10.1016/S1470-2045(22)00638-6. Epub 2022 Nov 4. Lancet Oncol. 2022. PMID: 36343656 Free PMC article. Clinical Trial.